Merck KGaA

Informe acción XTRA:MRK

Capitalización de mercado: €59.3b

Merck KGaA Crecimiento futuro

Future controles de criterios 1/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Merck KGaA de 11.4% y 5.1% por año respectivamente. Se prevé que el BPA crezca en un 11.4% al año. Se espera que la rentabilidad financiera sea de 12.7% en 3 años.

Información clave

11.4%

Tasa de crecimiento de los beneficios

11.38%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals24.5%
Tasa de crecimiento de los ingresos5.1%
Rentabilidad financiera futura12.71%
Cobertura de analistas

Good

Última actualización14 Aug 2026

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Actualización de narrativa • Aug 03

MRK: AI Partnerships And Bio-Techne Deal Will Shape Balanced Future Prospects

Analysts have raised their price target for Merck KGaA to €170 from €160, citing slightly higher assumed revenue growth, a modestly higher future P/E of about 22.4, and some pressure on projected profit margins following the agreed cash acquisition of Bio-Techne at €73 per share equivalent. Analyst Commentary Recent research on Merck KGaA is mixed, with analysts weighing the agreed Bio-Techne acquisition price of $73 per share against the company’s longer term growth drivers and current valuation levels.
Actualización de narrativa • Jul 20

MRK: Rich Bio Techne Deal And Downgrades Will Restrain Future Returns

Merck KGaA's fair value estimate has been adjusted from €112.00 to €121.00 as analysts factor in updated assumptions on revenue growth, profit margins and discount rates, alongside mixed reactions to the planned Bio Techne acquisition and its potential to support returns only under more optimistic scenarios. Analyst Commentary Recent research on Merck KGaA highlights a shift toward more cautious views, especially around the planned acquisition of Bio Techne and how it could affect valuation, execution risk, and the company’s long term growth profile.
Actualización de narrativa • Jul 06

MRK: Bio-Techne Deal And Life Science Recovery Will Drive Future Upside

Analysts have raised their fair value estimate for Merck KGaA from about €172 to roughly €177. This reflects higher blended price targets, even as they note that the planned Bio-Techne acquisition could justify the richer implied future P/E only in more optimistic scenarios.
Actualización de narrativa • Jun 22

MRK: Life Science Tools Recovery Will Support Future Upside Potential

Analysts recently adjusted their views on Merck KGaA after Street price targets diverged, including a cut to €129 at one firm that now sees a more balanced risk and reward, and a raise to €160 at another firm citing early signs of recovery in life science tools. Analyst Commentary Recent commentary on Merck KGaA reflects a split view, with some bullish analysts highlighting early signs of improvement in key segments such as life science tools, while others see the current share price as broadly aligned with the company's exposure to structural growth drivers.
Actualización de narrativa • Jun 06

MRK: Life Science Tools Recovery And Lower AI Risk Will Support Upside

Merck KGaA's updated analyst price target now centers around €160, up from €135, with analysts pointing to cautious optimism around life science tools, a more balanced risk and return profile, and sector wide reassessments of recovery potential and valuation. Analyst Commentary Recent research points to a mixed but generally firming stance on Merck KGaA.
Actualización de narrativa • May 23

MRK: Healthcare Resilience And Raised 2026 Guidance Will Support Future Upside

Narrative Update on Merck KGaA Analysts now see fair value for Merck KGaA at about €143, up from roughly €141, reflecting recent price target revisions and views that healthcare could appeal to investors given the current macro backdrop, geopolitical risks, and perceived lower exposure to AI disruption risks. Analyst Commentary Recent research snapshots show a mixed stance on Merck KGaA, with some analysts trimming price targets and others taking a more neutral starting point.
Actualización de narrativa • Apr 30

MRK: Healthcare Resilience And Sustainable Solvents Will Support Future Upside

The updated analyst price target for Merck KGaA moves modestly lower to about €141 from around €143, reflecting recent target cuts from firms citing a cautious macro backdrop and sector specific views, while still recognizing potential interest in healthcare as investors weigh geopolitical risk and AI related disruption. Analyst Commentary Recent research on Merck KGaA has focused on recalibrating expectations, with multiple firms trimming price targets and one major house initiating coverage with a neutral stance.
Actualización de narrativa • Apr 15

MRK: Reset Expectations And 2026 Guidance Will Shape Future Return Balance

Analysts have trimmed the fair value estimate for Merck KGaA from €127.00 to €112.00, reflecting recent reductions in Street price targets and a more cautious stance on profitability, despite slightly higher modeled revenue growth. Analyst Commentary Recent Street research on Merck KGaA has tilted more cautious, with several bearish analysts cutting price targets and reassessing the risk and reward balance.
Actualización de narrativa • Apr 01

MRK: Lower AI Disruption Risk And Margin Resilience Will Support Future Upside

Analysts have trimmed the fair value estimate for Merck KGaA from €187.48 to €172.13 as recent price target cuts and more cautious ratings have offset slightly higher revenue growth and profit margin assumptions, along with a lower future P/E multiple. Analyst Commentary Recent research shows a mixed set of opinions on Merck KGaA, but with some clear pockets of optimism that help frame the trimmed fair value estimate.
Actualización de narrativa • Mar 18

MRK: Healthcare Resilience And Limited AI Disruption Will Drive Future Upside

Analysts have trimmed the Merck KGaA fair value estimate from €143.88 to €143.20. This reflects recent cuts to Street price targets in light of a tougher macro backdrop, geopolitical risk and more tempered expectations around sector exposure to AI related disruption.
Actualización de narrativa • Mar 04

MRK: Margin Resilience And New TGCT Therapy Will Shape Future Upside

Analysts have lifted their price target on Merck KGaA to €130 from €125, citing slightly stronger assumptions for revenue growth, profit margins and future P/E, even as recent rating changes across the sector keep overall views balanced. Analyst Commentary Recent research on Merck KGaA reflects a split view, with some firms turning more cautious while others highlight steady execution and valuation support.
Actualización de narrativa • Feb 18

MRK: Margin Gains And HPC Buildout Will Shape Future Upside Potential

Analysts have raised their price target on Merck KGaA to €130 from €125, citing updated expectations for slightly lower revenue growth, a modestly higher discount rate, and a small uplift in projected profit margin and future P/E assumptions. Analyst Commentary Recent research on Merck KGaA presents a mixed picture, but there is a clear cluster of constructive views around valuation, profitability, and execution.
Actualización de narrativa • Feb 03

MRK: Mixed Rating Shifts Will Shape Perceived Balance Of Future Return Potential

Narrative Update: Merck KGaA Analysts have inched their average price target for Merck KGaA up by €5 to €130. This reflects updated views on earnings potential and risk after recent research, including a downgrade at Deutsche Bank and a price target adjustment at Barclays.
Actualización de narrativa • Jan 20

MRK: Refined Earnings Outlook Points To Balanced Future Return Potential

Analysts have lifted their fair value estimate for Merck KGaA to €127 from €105, citing updated assumptions for revenue growth, profit margins and future P/E multiples that are broadly in line with recent Street target moves, such as the new €130 level from Barclays. Analyst Commentary The recent move to a €130 price target from €125 sits broadly in line with the updated fair value estimate of €127, which suggests that expectations are being fine tuned rather than reset.
Actualización de narrativa • Jan 06

MRK: Future Earnings Power And HPC Expansion May Support Upside

Narrative Update on Merck KGaA Analysts have trimmed their price target for Merck KGaA by €20 to €130, citing updated assumptions that reflect a fair value of €184.63, a discount rate of 4.93%, revenue growth of 5.19%, a profit margin of 16.10%, and a future P/E of 23.44x. Analyst Commentary Recent Street research signals that analysts are reassessing Merck KGaA's valuation framework, with the latest work reflecting a price target of €130 compared with a prior level of €150.
Actualización de narrativa • Dec 21

MRK: Future Price Cut Signals Slowing Earnings Momentum Ahead

Analysts have trimmed their price target on Merck KGaA to EUR 130 from EUR 150, reflecting slightly lower long term revenue growth and margin expectations, even as they acknowledge the company's ability to sustain a higher future price to earnings multiple. Analyst Commentary Bearish analysts point to a more challenging backdrop for Merck KGaA, with reduced expectations for long term top line expansion and profitability prompting a reassessment of fair value.
Actualización de narrativa • Dec 07

MRK: Margin Strength And AI Deal Will Drive Future Upside

Analysts have trimmed their price target on Merck KGaA, cutting it by EUR 20 to EUR 130 as they factor in slightly softer long term revenue growth assumptions, even though profit margin expectations have improved modestly. Analyst Commentary Analysts are recalibrating their views on Merck KGaA, with the reduced price target reflecting a more measured stance on the company’s medium to long term prospects while acknowledging an improved profitability outlook.
Actualización de narrativa • Nov 23

MRK: New Leadership Change And AI Partnership Will Drive Shares Higher

Analysts have modestly lowered their price target for Merck KGaA from €150 to €130. They cite a combination of slightly reduced profit margin forecasts and an increased discount rate, even though there is a small uptick in expected revenue growth.
Actualización de narrativa • Nov 03

MRK: Future CEO Appointment Will Support Recovery and Restore Confidence

The analyst price target for Merck KGaA has been reduced from EUR 150 to EUR 130, as analysts cite softer growth expectations and recent earnings disappointments. Analyst Commentary Recent street research reflects a cautious tone among analysts regarding Merck KGaA, with a series of price target reductions and rating adjustments.
Actualización de narrativa • Oct 20

Global Biotechnology And Digital Automation Will Drive Future Healthcare

Analysts have trimmed their fair value estimate for Merck KGaA from €147.53 to €145.94. This change reflects a series of recent price target reductions and persistent concerns regarding growth prospects and limited near-term catalysts.
Actualización de narrativa • Sep 04

Global Biotechnology And Digital Automation Will Drive Future Healthcare

Merck KGaA's consensus price target remains unchanged at €147.53 as analysts adopt a more neutral stance following disappointing Q2 results, lowered guidance, and reduced near-term growth visibility. Analyst Commentary Disappointing Q2 report and weaker-than-expected operational performance.
User avatar
Nueva narrativa • Nov 24

AI-Driven Semiconductor Surge Powers Healthcare And Electronics To New Heights

Strong growth in semiconductor solutions and life sciences boosts Merck's Electronics and Process Solutions sectors, positively impacting future revenue and earnings.

Previsiones de crecimiento de beneficios e ingresos

XTRA:MRK - Estimaciones futuras de los analistas y datos financieros pasados (EUR Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
12/31/202823,6683,2523,1305,13013
12/31/202722,4362,8952,8804,79313
12/31/202621,3512,5202,8394,99313
6/30/202621,1352,3702,5784,232N/A
3/31/202620,9562,5322,4194,194N/A
12/31/202521,1022,6082,1453,932N/A
9/30/202521,2712,9572,1023,872N/A
6/30/202521,2192,8631,7993,813N/A
3/31/202521,3162,8182,1844,107N/A
12/31/202421,1562,7772,4204,586N/A
9/30/202420,9632,6962,1604,408N/A
6/30/202420,8702,6262,0524,205N/A
3/31/202420,8202,7221,9613,966N/A
12/31/202320,9932,8241,8973,784N/A
9/30/202321,4282,8931,9123,746N/A
6/30/202322,0613,0782,1984,042N/A
3/31/202322,3273,2422,3344,272N/A
12/31/202222,2323,3262,4914,259N/A
9/30/202221,7853,4732,7884,289N/A
6/30/202220,9523,3112,6584,204N/A
3/31/202220,2543,1882,7344,240N/A
12/31/202119,6873,0553,2344,616N/A
9/30/202119,0722,6893,1254,859N/A
6/30/202118,5462,7333,0734,562N/A
3/31/202117,7952,2782,7024,177N/A
12/31/202017,5341,9872,0023,477N/A
9/30/202017,3171,8841,6842,879N/A
6/30/202016,9241,4191,4982,640N/A
3/31/202016,7761,549N/A2,879N/A
12/31/201916,1521,292N/A2,856N/A
9/30/201915,6581,139N/A2,906N/A
6/30/201915,3541,118N/A2,706N/A
3/31/201915,096938N/A2,332N/A
12/31/201814,8361,071N/A2,219N/A
9/30/201814,5971,921N/A2,120N/A
6/30/201814,3642,218N/A2,147N/A
3/31/201814,3462,389N/A2,299N/A
12/31/201714,5172,548N/A2,696N/A
9/30/201714,6991,787N/A2,842N/A
6/30/201714,9061,628N/A3,152N/A
3/31/201715,0161,529N/A2,943N/A
12/31/201615,0241,629N/A2,518N/A
9/30/201614,6581,480N/A2,449N/A
6/30/201614,0541,387N/A2,253N/A
3/31/201613,4691,418N/A2,268N/A
12/31/201512,8451,109N/A2,195N/A
9/30/201512,3801,269N/A2,618N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (11.4% al año) de MRK es superior a la tasa de ahorro (2.1%).

Beneficios vs. Mercado: Se prevé que los beneficios (11.4% al año) de MRK crezcan menos que el mercado German (15.3% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de MRK crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (5.1% al año) de MRK crezcan más despacio que el mercado de German (6.8% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 5.1% al año) de MRK crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de MRK sea baja dentro de 3 años (12.7%).

Descubre empresas en crecimiento

7D

1Y

7D

1Y

7D

1Y

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/08/14 15:41
Precio de las acciones al final del día2026/08/14 00:00
Beneficios2026/06/30
Ingresos anuales2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Merck KGaA está cubierta por 42 analistas. 13 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Odile RundquistBaader Helvea Equity Research
Gerhard SchwarzBaader Helvea Equity Research
Charles PitmanBarclays